Nature Communications (Dec 2022)
Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features
- Dustin J. Flanagan,
- Raheleh Amirkhah,
- David F. Vincent,
- Nuray Gundaz,
- Pauline Gentaz,
- Patrizia Cammareri,
- Aoife J. McCooey,
- Amy M. B. McCorry,
- Natalie C. Fisher,
- Hayley L. Davis,
- Rachel A. Ridgway,
- Jeroen Lohuis,
- Joshua D. G. Leach,
- Rene Jackstadt,
- Kathryn Gilroy,
- Elisa Mariella,
- Colin Nixon,
- William Clark,
- Ann Hedley,
- Elke K. Markert,
- Douglas Strathdee,
- Laurent Bartholin,
- Keara L. Redmond,
- Emma M. Kerr,
- Daniel B. Longley,
- Fiona Ginty,
- Sanghee Cho,
- Helen G. Coleman,
- Maurice B. Loughrey,
- Alberto Bardelli,
- Timothy S. Maughan,
- Andrew D. Campbell,
- Mark Lawler,
- Simon J. Leedham,
- Simon T. Barry,
- Gareth J. Inman,
- Jacco van Rheenen,
- Philip D. Dunne,
- Owen J. Sansom
Affiliations
- Dustin J. Flanagan
- Cancer Research UK Beatson Institute
- Raheleh Amirkhah
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- David F. Vincent
- Cancer Research UK Beatson Institute
- Nuray Gundaz
- Cancer Research UK Beatson Institute
- Pauline Gentaz
- Cancer Research UK Beatson Institute
- Patrizia Cammareri
- Cancer Research UK Beatson Institute
- Aoife J. McCooey
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Amy M. B. McCorry
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Natalie C. Fisher
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Hayley L. Davis
- Wellcome Trust Centre for Human Genetics, University of Oxford
- Rachel A. Ridgway
- Cancer Research UK Beatson Institute
- Jeroen Lohuis
- Department of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute
- Joshua D. G. Leach
- Cancer Research UK Beatson Institute
- Rene Jackstadt
- Cancer Research UK Beatson Institute
- Kathryn Gilroy
- Cancer Research UK Beatson Institute
- Elisa Mariella
- Department of Oncology, University of Torino
- Colin Nixon
- Cancer Research UK Beatson Institute
- William Clark
- Cancer Research UK Beatson Institute
- Ann Hedley
- Cancer Research UK Beatson Institute
- Elke K. Markert
- Cancer Research UK Beatson Institute
- Douglas Strathdee
- Cancer Research UK Beatson Institute
- Laurent Bartholin
- INSERM Centre de Recherche en Cancérologie de Lyon
- Keara L. Redmond
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Emma M. Kerr
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Daniel B. Longley
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Fiona Ginty
- GE Global Research Center
- Sanghee Cho
- GE Global Research Center
- Helen G. Coleman
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Maurice B. Loughrey
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Alberto Bardelli
- Department of Oncology, University of Torino
- Timothy S. Maughan
- CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford
- Andrew D. Campbell
- Cancer Research UK Beatson Institute
- Mark Lawler
- The Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast
- Simon J. Leedham
- Wellcome Trust Centre for Human Genetics, University of Oxford
- Simon T. Barry
- Bioscience, Oncology R&D, AstraZeneca
- Gareth J. Inman
- Cancer Research UK Beatson Institute
- Jacco van Rheenen
- Department of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute
- Philip D. Dunne
- Cancer Research UK Beatson Institute
- Owen J. Sansom
- Cancer Research UK Beatson Institute
- DOI
- https://doi.org/10.1038/s41467-022-35134-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
It remains critical to identify colorectal cancers (CRC) that will disseminate as early as possible. Here, the authors identify CRC tumours that are aggressive and prone to early dissemination, characterised by epithelial TGFβ and growth-factor signalling - which could be targeted with MEK/EGFR inhibitors.
